

September 2025

CURRICULUM VITAE **SHIRIN FARJADIAN**

Personal Background:

Name: Shirin Farjadian

Date of birth: March 5, 1968

Nationality: Iranian

Sex: Female

Address: Room # 316, Department of Immunology
71348-45794 Shiraz University of Medical Sciences,
Shiraz, Iran.

E-mail: farjadsh@sums.ac.ir

Tel/Fax: (98) 71-32351575

Positions:

- From Oct 2023 till present: Head of Immunology Department, SUMS
- From May 2016: Full professor, Department of Immunology, SUMS
- From June 2010-May 2016: Associate professor, Department of Immunology, SUMS
- From March 2006-May 2010: Assistant professor, Department of Immunology, SUMS
- From April 1998-April 2006: Instructor of Immunology and Molecular Biology and Director of Molecular Biology Lab and, Department of Immunology, SUMS
- From April 1996-March 1998: Research assistant, Department of Immunology, SUMS

Certifications:

2006: PhD degree in Immunology, SUMS, Shiraz, Iran.

1995: MS degree in Microbiology, SUMS, Shiraz, Iran.

1991: BS degree in Biology, Shiraz University, Shiraz, Iran.

Memberships:

- Iranian Society for Immunology and Allergy
- European Federation for Immunogenetics (EFI) from 2009

Publications in International Journals:

1. Moshfeghinia R, Kavari K, Mostafavi S, Sanaei E, **Farjadian S**, Javanbakht A.J. Haematological markers of inflammation in major depressive disorder (MDD) patients with suicidal behaviour: A systematic review and meta-analysis. *Affect Disord.* 2025;385:119371.
2. Masoudi S, Kalani M, Alavianmehr A, Mosleh-Shirazi MA, Mortazavi SMJ, **Farjadian S**. Sequential radiation exposure: uncovering the potential of low dose ionizing radiation in mitigating high dose effects on immune cells. *Int J Radiat Biol.* 2024;100(7):1009.
3. Halimi H, Mirzazadeh S, Kalantar K, Hajimaghsoodi M, Ramzi M, **Farjadian S**. Activating KIR/HLA-I combinations as a risk factor of adult B-ALL. *Hum Immunol.* 2024;85(2):110750.
4. Tabaei S, Haghshenas MR, Ariafar A, Gilany K, Stensballe A, **Farjadian S**, Ghaderi A. Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity. *Clin Proteomics.* 2023;20(1):28.
5. Mirzazadeh S, Bemani P, Halimi H, Sanaee MN, Karami N, Ramzi M, **Farjadian S**. Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in Iranian patients. *Sci Rep.* 2023;13(1):11456.
6. Halimi H, **Farjadian S**. Cholesterol: An important actor on the cancer immune scene. *Front Immunol.* 2022;13:1057546.
7. Kashef S, Moghtaderi M, Hatami HR, Kalani M, Alyasin S, Nabavizadeh H, **Farjadian S**. Evaluation of T Cell Proliferation Using CFSE Dilution Assay: A Comparison between Stimulation with PHA and Anti-CD3/Anti-CD28 Coated Beads. *Iran J Allergy Asthma Immunol.* 2022;21(4):458-466.
8. Talezadeh Shirazi P, **Farjadian S**, Dabbaghmanesh MH, Jonaidi H, Alavianmehr A, Kalani M, Emadi L. Eugenol: A New Option in Combination Therapy with Sorafenib for the Treatment of Undifferentiated Thyroid Cancer. *Iran J Allergy Asthma Immunol.* 2022;21(3):313-321.
9. Jalali S, Farhadi A, Rafiei Dehbidi G, **Farjadian S**, Sharifzadeh S, Ranjbaran R, Seyyedi N, Namdari S, Behzad-Behbahani A. The Pathogenic Aspects of Human Parvovirus B19 NS1 Protein in Chronic and Inflammatory Diseases. *Interdiscip Perspect Infect Dis.* 2022;2022:1639990.
10. Mojtahedi Z, **Farjadian S**. Awareness of Obesity-Related Cancers: A Complex Issue. *Int J Environ Res Public Health.* 2022;19(11):6617.

11. Nejabat S, Haghshenas MR, **Farjadian S**. Allergenome profiling of *Vespa orientalis* venom by serum IgE in patients with anaphylactic reaction to this hornet sting. *Toxicon*. 2022;214:130-135.
12. Sepahi N, Alyasin S, Kanannejad Z, Esmaeilzadeh H, Mohammadalizadeh Shirazi F, Babaei M, **Farjadian S**. Identification of the Most Common Allergens of *Acer velutinum* Pollen. *Iran J Allergy Asthma Immunol*. 2022;21(1):81-85.
13. Amirkhani Z, Alavi MS, Kalani M, Alavianmehr A, **Farjadian S**. Immunomodulatory Effects of Omega-3 Fatty Acids in Patients with Differentiated Thyroid Cancer Before or After Radioiodine Ablation. *Iran J Immunol*. 2022;19(1):7.
14. Ashouri E, Rajalingam K, Barani S, **Farjadian S**, Ghaderi A, Rajalingam R. Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk. *Sci Rep*. 2021;11(1):7932.
15. Yazdanpanah P, Alavianmehr A, Ghaderi A, Monabati A, Montazer M, Tahmasbi K, **Farjadian S**. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC. *Breast Dis*. 2021 Jan 25. doi: 10.3233/BD-201049. Online ahead of print.
16. Alavianmehr A, Mansouri M, Ramzi M, Faghih M, Monabati A, Arandi N, Faghih Z, **Farjadian S**. Association of killer-cell immunoglobulin-like receptor genes with acute myelogenous leukaemia. *Int J Immunogenet*. 2020;47(6):512-521.
17. Monjezi MR, Fouladseresht H, Farjadian S, Gharesi-Fard B, Khosropanah S, Doroudchi M.T Cell Proliferative Responses and IgG Antibodies to β 2GPI in Patients with Diabetes and Atherosclerosis. *Endocr Metab Immune Disord Drug Targets*. 2021;21(3):495-503.
18. Aghajari S, Mortazavi SMJ, Kalani M, Nematolahi S, Habibzadeh P, **Farjadian S**. The Immunomodulatory Effect of Radiofrequency Electromagnetic Field on Serum Cytokine Levels in A Mouse Model of Hindlimb Unloading. *Cell J*. 2021;22(4):401-405.
19. Mansouri M, Villard J, Ramzi M, Alavianmehr A, **Farjadian S**. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT. *Hum Immunol*. 2020;81(6):285-292.
20. Kardeh S, Mazloomrezaei M, Dianatpour M, **Farjadian S**. Universal off-the-shelf skin substitutes for cosmetic and reconstructive surgery. *Burns*. 2019. pii: S0305-4179(19)30857-5.

21. Moghtaderi M, **Farjadian S**, Hossieni Teshnizi S, Hadibarhaghtalab M. Allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization in patients with uncontrolled asthma: An experience from Southwestern Iran. *Med J Islam Repub Iran*. 2019;33:95.
22. Moghtaderi M, Ashraf MA, Teshnizi SH, Nabavizadeh H, **Farjadian S**, Fereidouni M. The level of allergens in dust samples collected from selected schools in Shiraz, Iran and its asthma-risk implications. *Allergol Immunopathol (Madr)*. 2020;48(1):90-94.
23. **Farjadian S**, Bonatti F, Soriano A, Reina M, Adorni A, Graziano C, Moghtaderi M, Percesepe A, Romeo G, Martorana D. A new MEFV gene mutation in an Iranian patient with familial Mediterranean fever. *Reumatismo*. 2019;71(2):85-87.
24. Esmaeilzadeh H, **Farjadian S**, Alyasin S, Nemati H, Nabavizadeh H, Esmaeilzadeh E. Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics. *Iran J Pharm Res*. 2019;18(1):506-522.
25. **Farjadian S**, Fakhraei B, Niknam Z, Nasiri M, Azad A, Farjam M, Nikseresht A. Polymorphisms of serotonin transporter gene and psychological status in patients with multiple sclerosis. *Iran J Neurol*. 2018;17(3):105-110.
26. **Farjadian S**, Tabebordbar M, Mokhtari M, Safaei A, Malekzadeh M, Ghaderi A. HLA-G Expression in Tumor Tissues and Soluble HLA-G Plasma Levels in Patients with Gastrointestinal Cancer. *Asian Pac J Cancer Prev*. 2018;19(10):2731-2735.
27. Golmoghaddam H, **Farjadian S**, Khosropanah S, Dehghani P, Doroudchi M. Lower Frequency of HLA-DRB1*01 in Southwestern Iranian Patients with Atherosclerosis. *Iran J Immunol*. 2018;15(3):197-206.
28. **Farjadian S**, Moghtaderi M, Hoseini-Pouya BA, Ebrahimpour A, Nasiri M. ADAM33 gene polymorphisms in Southwestern Iranian patients with asthma. *Iran J Basic Med Sci*. 2018;21(8):813-817.
29. Noorpisheh Ghadimi S, **Farjadian S**, Hatam GR, Kalani M, Sarkari B. Vaccination with Live Attenuated L. Major and TLR4 Agonist Promotes a Th1 Immune Response and Induces Protection against L. Major Infection in BALB/c Mice. *Iran J Immunol*. 2018;15(2):74-83.
30. Alyasin S, Moghtaderi M, **Farjadian S**, Babaei M, Teshnizi SH. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. *Electron Physician*. 2018;10(1):6273-6278.

31. Hamed A, Yousefi G, **Farjadian S**, Bour Bour MS, Parhizkar E. Physicochemical and Immunomodulatory Properties of Gum Exudates Obtained from *Astragalus myriacanthus* and Some of Its Isolated Carbohydrate Biopolymers. *Iran J Pharm Res*. 2017;16(4):1520-1530.
32. Khodabandeh Shahraki P, Alavian-Mehr A, **Farjadian S**. HLA-G: Facts and Fictions. *Asian Pac J Cancer Biol*. 2018;3(2):1-9.
33. Khodabandeh Shahraki P, Zare Y, Azarpira N, Hosseinzadeh M, **Farjadian S**. Prognostic Value of HLA-G in Malignant Liver and Pancreas Lesions. *Iran J Immunol*. 2018;15(1):28-37.
34. Moghtaderi M, Torab Jahromi M, **Farjadian S**, Ghassemi P, Hosseini Teshnizi S. Decreased Sensitization to Aeroallergens among Southwestern Iranian Male Farmers. *Iran J Allergy Asthma Immunol*. 2017;16(4):307-312.
35. Moghtaderi M, **Farjadian S**, Aflaki E, Honar N, Alyasin S, Babaei M. Re: HLA is better than serological screening for celiac diseases in rheumatological arthritis. *Turk J Gastroenterol*. 2017;28(3):228.
36. Sahakyan H, Hooshkar Kashani B, Tamang R, Kushniarevich A, Francis A, Costa MD, Pathak AK, Khachatryan Z, Sharma I, van Oven M, Parik J, Hovhannisyan H, Metspalu E, Pennarun E, Karmin M, Tamm E, Tambets K, Bahmanimehr A, Reisberg T, Reidla M, Achilli A, Olivieri A, Gandini F, Perego UA, Al-Zahery N, Houshmand M, Sanati MH, Soares P, Rai E, Šarac J, Šarić T, Sharma V, Pereira L, Fernandes V, Černý V, **Farjadian S**, et al. Origin and spread of human mitochondrial DNA haplogroup U7. *Sci Rep*. 2017;7:46044.
37. Haghighat M, Moghtaderi M, **Farjadian S**. Genetic Analysis of Southwestern Iranian Patients with Familial Mediterranean Fever. *Rep Biochem Mol Biol*. 2017;5(2):117-120.
38. Sattarinezhad E, Panjehshahin MR, Torabinezhad S, Kamali-Sarvestani E, **Farjadian S**, Pirsalami F, Moezi L. Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats. *Iran J Med Sci*. 2017;42(2):170-178.
39. Moghtaderi M, Hosseini Teshnizi S, **Farjadian S**. Sensitization to common allergens among patients with allergy in major Iranian cities: A systemic review and meta-analysis. *Epidemiol Health*. 2017;39:e2017007.
40. Moghtaderi M, **Farjadian S**, Aflaki E, Honar N, Alyasin S, Babaei M. Screening of patients with juvenile idiopathic arthritis and those with rheumatoid arthritis for celiac disease in southwestern Iran. *Turk J Gastroenterol*. 2016;27(6):521-524.

41. Nazari N, **Farjadian S**. Natural Killer Cell Cytotoxicity Against SKOV3 after HLA-G Downregulation by shRNA. Iran J Immunol. 2016;13(3):178-85.
42. **Farjadian S**, Moghtaderi M, Kalani M, Gholami T, Hosseini Teshnizi S. Effects of omega-3 fatty acids on serum levels of T-helper cytokines in children with asthma. Cytokine. 2016;85:61-66.
43. Moghtaderi M, **Farjadian S**, Fereidouni M, Nasiri M, Nejat A. Indoor Dust Allergen Levels in the Homes of Patients with Childhood Asthma: An Experience From Southwestern Iran. Iran J Allergy Asthma Immunol. 2016;15(2):132-7.
44. Moghtaderi M, Zarei M, **Farjadian S**, Shamsizadeh S. Prediction of the impact of air pollution on rates of hospitalization for asthma in Shiraz based on air pollution indices in 2007-2012. Open Journal of Air Pollution. 2016;5:37-43
45. Zaeri S, **Farjadian S**, Emamghoreishi M. Decreased levels of canonical transient receptor potential channel 3 protein in the rat cerebral cortex after chronic treatment with lithium or valproate. Res Pharm Sci. 2015;10(5):397-406.
46. Moghtaderi M, **Farjadian S**, Hosseini Z, Raayat A. Increased risk of horse sensitization in southwestern Iranian horse riders. Int J Occup Med Environ Health. 2015;28(5):909-13
47. Hamed A, **Farjadian S**, Karami MR. Immunomodulatory Properties of Taranjebin (Camel's Thorn) Manna and Its Isolated Carbohydrate Macromolecules. J Evid Based Complementary Altern Med. 2015;20(4):269-74.
48. Gholijani N, Gharagozloo M, **Farjadian S**, Amirghofran Z. Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophages. J Immunotoxicol. 2016;13(2):157-64.
49. **Farjadian S**, Khajoei Nejad L, Fazeli M, Askari Firouzjaei H, Zaeri S. Doxorubicin cytotoxicity in combination with soy isoflavone daidzein on MCF-7 breast cancer cells. Mal J Nutr. 2015;21(1):67-73.
50. Hamed A, **Farjadian S**, Karami MR. Immunomodulatory properties of Trehala manna decoction and its isolated carbohydrate macromolecules. J Ethnopharmacol. 2015;162:121-6.
51. Moghtaderi M, **Farjadian S**, Reihani I. Sensitization to plant food allergens in patients with asthma. Indian J Allergy Asthma Immunol 2015;29:24-7.

52. Farjam M, Beigi Zarandi FB, **Farjadian S**, Geramizadeh B, Nikseresht AR, Panjehshahin MR. Inhibition of NR2B-Containing N-methyl-D-Aspartate Receptors (NMDARs) in Experimental Autoimmune Encephalomyelitis, a Model of Multiple Sclerosis. *Iran J Pharm Res*. 2014;13(2):695-705.
53. **Farjadian S**, Moghtaderi M, Zuntini R, Ferrari S. Rare large homozygous CFTR gene deletion in an Iranian patient with cystic fibrosis. *World J Clin Cases*. 2014;2(8):395-7.
54. Moghtaderi M, **Farjadian S**, Abbaszadeh Hasiri M. Animal allergen sensitization in veterinarians and laboratory animal workers. *Occup Med (Lond)*. 2014;64(7):516-20.
55. Ebrahimkhani S, **Farjadian S**, Ebrahimi M. The Royan Public Umbilical Cord Blood Bank: Does It Cover All Ethnic Groups in Iran Based on HLA Diversity? *Transfus Med Hemother*. 2014;41(2):134-8.
56. Underhill PA, Poznik GD, Rootsi S, Järve M, Lin AA, Wang J, Passarelli B, Kanbar J, Myres NM, King RJ, Di Cristofaro J, Sahakyan H, Behar DM, Kushniarevich A, Sarac J, Saric T, Rudan P, Pathak AK, Chaubey G, Grugni V, Semino O, Yepiskoposyan L, Bahmanimehr A, **Farjadian S**, Balanovsky O, Khusnutdinova EK, Herrera RJ, Chiaroni J, Bustamante CD, Quake SR, Kivisild T, VILLEMS R. The phylogenetic and geographic structure of Y-chromosome haplogroup R1a. *Eur J Hum Genet*. 2015;23(1):124-31.
57. Najib K, Moghtaderi M, **Farjadian S**, Falahzadeh E. Low Postprandial Circulating Inactive Ghrelin: Role of Early Satiety in Undernourished Children. *Indian J Pediatr*. 2014;81(11):1147-50.
58. Zahmatkeshan M, Fallahzadeh E, Moghtaderi M, Najib KS, **Farjadian S**. Attitudes of medical students and staff toward organ donation in cases of brain death: a survey at Shiraz University of Medical Sciences. *Prog Transplant*. 2014;24(1):91-6.
59. Tofanelli S, Bertoncini S, **Farjadian S**, Ghaderi A, Ferri G, Romeo G, Luiselli D. Increased efficiency in geographic ancestry assignment and human identification by combining lineage profiles: The case of the iranians. *Am J Hum Biol*. 2014;26(3):413-6.
60. Derenko M, Malyarchuk B, Bahmanimehr A, Denisova G, Perkova M, **Farjadian S**, Yepiskoposyan L. Complete mitochondrial DNA diversity in Iranians. *PLoS One*. 2013;8(11):e80673.
61. **Farjadian S**, Moghtaderi M, Fakhraei B, Nasiri M, Farjam M. Association between serotonin transporter gene polymorphisms and childhood asthma. *J Asthma*. 2013;50(10):1031-5.

62. **Farjadian S**, Fakhraei B, Moeini M, Nasiri M, Fattahi MR. Serotonin transporter gene polymorphisms in Southwestern Iranian patients with irritable bowel syndrome. *Arab J Gastroenterol*. 2013;14(2):59-62.
63. **Farjadian S**, Norouzian M, Younesi V, Ebrahimpour A, Lotfi R. Hyperthermia Increases Natural Killer Cell Cytotoxicity against SW-872 Liposarcoma Cell Line. *Iran J Immunol*. 2013;10(2):93-102.
64. **Farjadian S**, Safi S. Genetic connections among Turkic-speaking Iranian ethnic groups based on HLA class II gene diversity. *Int J Immunogenet*. 2013;40(6):509-14.
65. **Farjadian S**, Rahimifar S, Erfani N, Lotfi R. Effect of thermal stress on MICA/B induction in a human liposarcoma cell line. *Iran J Immunol*. 2013;10(1):31-9.
66. **Farjadian S**, Moghtaderi M, Kashef S, Alyasin S, Najib Kh, Saki F. Clinical and genetic features in patients with cystic fibrosis in southwestern Iran. *Iran J Pediatr*. 2013;23(2): 212-5.
67. **Farjadian S**. The significance of HLA typing in transplantation. *J Nephropathology*. 2012;1(3): 160-1.
68. **Farjadian S**, Moghtaderi M, Kashef S, Alyasin S. Sensitization to food allergens in Iranian children with mild to moderate persistent asthma. *World J Pediatr*. 2012;8(4):317-20.
69. Ashjzadeh N, Poursadeghfard M, **Farjadian S**. Factor V G1691A and prothrombin G20210A gene polymorphisms among Iranian patients with cerebral venous thrombosis. *Neurology Asia* 2012;17(3):199-203.
70. Moghtaderi M, **Farjadian S**, Momeni Z, Najib K. Natural latex sensitization and respiratory function among workers in latex glove factories: a pilot study. *J Occup Environ Hyg*. 2012;9(10):D183-5.
71. Pourshahidi S, Fakhri F, Ebrahimi H, Fakhraei B, Alipour A, Ghapanchi J, **Farjadian S**. Lack of association between *Helicobacter pylori* infection and oral lichen planus. *Asian Pac J Cancer Prev*. 2012;13(5):1745-7.
72. Rootsi S, Myres NM, Lin AA, Järve M, King RJ, Kutuev I, Cabrera VM, Khusnutdinova EK, Varendi K, Sahakyan H, Behar DM, Khusainova R, Balanovsky O, Balanovska E, Rudan P, Yepiskoposyan L, Bahmanimehr A, **Farjadian S**, Kushniarevich A, Herrera RJ, Grugni V, Battaglia V, Nici C, Crobu F, Karachanak S, Hooshier Kashani B, Houshmand M, Sanati MH, Toncheva D, Lisa A, Semino O, Chiaroni J, Cristofaro JD, Villems R, Kivisild T, Underhill PA. Distinguishing the co-ancestries of haplogroup G Y-

- chromosomes in the populations of Europe and the Caucasus. *Eur J Hum Genet.* 2012;20(12):1275-82.
73. Moghtaderi M, **Farjadian S**, Kashef S, Tavakoli M, Alyasin S, Afrasiabi M, Orooj M. Specific IgE to Common Food Allergens in Children with Atopic Dermatitis. *Iran J Immunol.* 2012;9(1):32-8.
 74. Moghtaderi M, **Farjadian S**, Kashef S. Lung function and skin prick test in wheat flour mill workers in Southwestern Iran. *J Occup Environ Hyg.* 2012;9(3):D52-4.
 75. Ioana M, Ferwerda B, **Farjadian S**, Ioana L, Ghaderi A, Oosting M, Joosten LA, van der Meer JW, Romeo G, Luiselli D, Dediu D, Netea MG. High variability of TLR4 gene in different ethnic groups in Iran. *Innate Immun.* 2012;18(3):492-502.
 76. **Farjadian S**, Sazzini M, Tofanelli S, Castrì L, Taglioli L, Pettener D, Ghaderi A, Romeo G, Luiselli D. Discordant patterns of mtDNA and ethno-linguistic variation in 14 Iranian Ethnic groups. *Hum Hered.* 2011;72(2):73-84.
 77. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, **Farjadian S**, Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. *J Gastroenterol Hepatol.* 2009;24(6):1119-22.
 78. Yousefipour GA, Salami Z, **Farjadian S**. Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients. *Iran J Immunol.* 2009;6(2):99-102.
 79. Ashouri E, **Farjadian S**, Reed EF, Ghaderi A, Rajalingam R. KIR gene content diversity in four Iranian populations. *Immunogenetics.* 2009;61(7):483-92.
 80. Sazzini M, Zuntini R, **Farjadian S**, Quinti I, Ricci G, Romeo G, Ferrari S, Calafell F, Luiselli D. An evolutionary approach to the medical implications of the tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) gene. *Genes Immun.* 2009;10(6):566-78.
 81. **Farjadian S**, Ota M, Inoko H, Ghaderi A. The genetic relationship among Iranian ethnic groups: an anthropological view based on HLA class II gene polymorphism. *Mol Biol Rep.* 2009; 36(7):1943-50.
 82. Kashef S, Ghazizadeh F, Derakhshan A, **Farjadian S**, Alyasin S. Antigen-Specific Antibody Response in Juvenile-Onset SLE Patients Following Routine Immunization with Tetanus Toxoid. *Iran J Immunol.* 2008; 5(3):181-4.

83. **Farjadian S**, Lotfazar M, Ghaderi A. Analysis of Human Leukocyte Antigen class II Gene Polymorphism in Iranian Patients with Papillon-Lefevre Syndrome: a Family Study. *Iran J Immunol*. 2008; 5(3):171-6.
84. **Farjadian S**, Ghaderi A. Iranian Lurs Genetic Diversity: An Anthropological View Based on HLA Class II Profiles. *Iran J Immunol*. 2006; 3(3):106-13.
85. Amani D, **Farjadian S**, Ghaderi A. The frequency of transforming growth factor-beta1 gene polymorphisms in a normal southern Iranian population. *Int J Immunogenet*. 2008; 35(2):145-51.
86. **Farjadian S**, Kiyanimanesh N, Abbaszadegan A, Lotfazar M. HLA class I gene polymorphism in Iranian patients with Papillon-Lefevre Syndrome. *Iran J Immunol*. 2007; 4(4):241-5.
87. **Farjadian S**, Ghaderi A. HLA class II similarities in Iranian Kurds and Azeris. *Int J Immunogenet*. 2007; 34(6):457-63.
88. **Farjadian S**, Ghaderi A. HLA class II genetic diversity in Arabs and Jews of Iran. *Iran J Immunol*. 2007; 4(2):85-93.
89. **Farjadian S**, Moqadam FA, Ghaderi A. HLA class II gene polymorphism in Parsees and Zoroastrians of Iran. *Int J Immunogenet*. 2006; 33(3):185-91.
90. Mojtahedi Z, Naeimi S, **Farjadian S**, Omrani GR, Ghaderi A. Association of IL-18 promoter polymorphisms with predisposition to Type 1 diabetes. *Diabet Med*. 2006; 23(3):235-9.
91. Mojtahedi Z, **Farjadian S**, Ghaderi A. Does autoantigen administration inhibit recurrence of type 1 diabetes in transplanted islets? *Med Hypotheses*. 2005; 64(5):986-8.
92. Gharagozloo M, Doroudchi M, **Farjadian S**, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. *Immunol Lett*. 2005; 96(2):277-81.
93. Karimi M, Yavarian M, Delbini P, Harteveld CL, **Farjadian S**, Fiorelli G, Giordano PC. Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in beta-thalassemia major and the first E277K homozygous. *Hematol J*. 2004; 5(6):524-7.
94. Enayat MS, Karimi M, Chana G, **Farjadian S**, Theophilus BD, Hill FG. Mutation analysis in F9 gene of 17 families with haemophilia B from Iran. *Haemophilia*. 2004; 10(6):751-5.

95. **Farjadian S**, Naruse T, Kawata H, Ghaderi A, Bahram S, Inoko H. Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. *Tissue Antigens*. 2004; 64(5):581-7.
96. Kalantari T, Mostafavi H, Pezeshki AM, **Farjadian S**, Doroudchi M, Yeganeh F, Ghaderi A. Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. *Autoimmunity*. 2003; 36(5):313-6.
97. **Farjadian S**, Asadi E, Doroudchi M, Dehaghani AS, Tabei SZ, Kumar VP, Ghaderi A. High risk HPV types in southern Iranian patients with cervical cancer. *Pathol Oncol Res*. 2003; 9(2):121-5.
98. Karimi M, Martinez di Montemuros F, Danielli MG, **Farjadian S**, Afrasiabi A, Fiorelli G, Cappellini MD. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran. *Haematologica*. 2003; 88(3):346-7.
99. Karimi M, Yarmohammadi H, **Farjadian S**, Zeinali S, Moghaddam Z, Cappellini MD, Giordano PC. Beta-thalassemia intermedia from southern Iran: IVS-II-1 (G-->A) is the prevalent thalassemia intermedia allele. *Hemoglobin*. 2002; 26(2):147-54.
100. Dehaghani AS, Amirzargar A, **Farjadian S**, Ghaderi A. HLA-DQBI alleles and susceptibility to cervical squamous cell carcinoma in Southern Iranian patients. *Pathol Oncol Res*. 2002; 8(1):58-61.
101. Amirzargar A, Mytilineos J, **Farjadian S**, Doroudchi M, Scherer S, Opelz G, Ghaderi A. Human leukocyte antigen class II allele frequencies and haplotype association in Iranian normal population. *Hum Immunol*. 2001; 62(11):1234-8.
102. Pezeshki AM, **Farjadian S**, Talei A, Vasei M, Gharesi-Fard B, Doroudchi M, Ghaderi A. p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. *Cancer Lett*. 2001; 169(1):69-75.
103. Ghaderi A, Talei A, Gharesi-Fard B, **Farjadian S**, Amirzargar A, Vasei M. HLA-DBR1 alleles and the susceptibility of Iranian patients with breast cancer. *Pathol Oncol Res*. 2001; 7(1):39-41.
104. Ghaderi A, Talei A, **Farjadian S**, Mosalaei A, Doroudchi M, Kimura H. Germline BRCA1 mutations in Iranian women with breast cancer. *Cancer Lett*. 2001; 165(1):87-94.
105. Amirzargar A, Mytilineos J, Yousefipour A, **Farjadian S**, Scherer S, Opelz G, Ghaderi A. HLA class II (DRB1, DQA1 and DQB1) associated

genetic susceptibility in Iranian multiple sclerosis (MS) patients. *Eur J Immunogenet* 1998; 25(4):297-301.

Training and Workshops:

- HLA typing by Sequence Based Typing (SBT): **January to July, 2003, Human Life Science, Toki University, Isehara, Japan.**
- Biotest Co. meeting, **May 24-29, 2006, Dreieich, Germany.**
- Mitochondrial DNA analysis: **January to July, 2008, Anthropology department, Bologna University, Italy.**
- Senior visiting fellowship: **September to November 2013, Anthropology department, Bologna University, Italy.**

Presentations in International Congress:

1. **Farjadian S**, Mansouri M, Villard J, Ramzi M. The impact of KIR/HLA-I combinations on the one-year prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. *32nd European Immunogenetics and Histocompatibility Conference. May 9-12, 2018, Venice Lido, Italy.*
2. **Farjadian S**, Moghtaderi M. The effect of omega-3 on Th1/Th2/Th9/Th17/Th22 serum levels in childhood asthma. *ICI 2016, Aug 21-26, 2016. Melbourne, Australia.*
3. **Farjadian S**, Nazari N. Natural killer cell cytotoxicity against tumor cell lines after HLA-G downregulation by shRNA. *The 29th European Immunogenetics and Histocompatibility Conference. April 26-29, 2015; Geneva, Switzerland.*
4. **Farjadian S**, Alyasin Z, Porshahidi S. Genetic variations of HLA in Iranian patients with erosive oral lichen planus. *The 28th European Immunogenetics and Histocompatibility Conference. June 25-28, 2014; Stockholm, Sweden.*
5. **Farjadian S**, Moghtaderi M, Kashef S. Lung function and skin prick test in wheat flour mill workers in Southwestern Iran. *The European Academy of Allergy and Clinical Immunology (EAACI) 31st Annual meeting, June 16-20, 2012, Geneva, Switzerland.*
6. **Farjadian S**, Hoseini Nasab F, Rahimifar S, Erfani N, Lotfi R. The Effect of Hyperthermia on the Induction of ULBPs in a Human Liposarcoma Cell line. *2011 Joint Annual Meeting SIICA-DGFI., Sep 28-Oct 1, 2011, Riccione, Italy.*
7. **Farjadian S**, Rahimifar S, Hossaini-nasab F, Erfani N, Lotfi R, Ghaderi A. Does hyperthermia increase the susceptibility of liposarcoma cells to NK cell

lysis? *14th International Congress of Immunology. August 22-27, 2010. Kobe, Japan.*

8. **Farjadian S**, Pettener D, Luiselli D, Castri L, Ghaderi A, Romeo G. Mitochondrial DNA haplogroups and HLA class II gene variation in ethnolinguistic isolates of Iran. *23th European Immunogenetics and Histocompatibility Conference. May 9-12, 2009. Ulm, Germany.*
9. **Farjadian S**, Ghaderi A. The Genetic Relationship among Iranian Ethnic Groups. *The 9th Iranian Congress of Biochemistry & the 2nd International Congress of Biochemistry and Molecular Biology. October 29-November 1, 2007. Shiraz, Iran.*
10. **Farjadian S**, Ghaderi A. The Genetic Relationship among Eleven Persian Ethnic Groups: An Anthropological View Based on HLA Class II Gene Polymorphism. *7th Annual Meeting of FOCIS, June 7-11, 2007; San Diego, California, USA.*
11. **Farjadian S**, Ghaderi A. Variation of HLA class II in two Iranian ethnic groups (Arabs and Jews). *1st Joint Meeting of European National Societies of Immunology and 16th European Congress of Immunology. September 6-9, 2006; Paris, France.*
12. **Farjadian S**, Ghaderi A. HLA class II gene polymorphism in seven Iranian ethnic groups. *14th International HLA and Immunogenetics Workshop, November 29-December 2, 2005; Melbourne, Australia.*
13. **Farjadian S**, Naruse T, Kawata H, Ghaderi A, Bahram S, Inoko H. Molecular Analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. *12th international Congress of Immunology and 4th Annual Conference of FOCIS, July 18-23, 2004; Montreal, Canada.*
14. **Farjadian S**, Kalantari T, Pezeshki AM, Mostafavi HA, Doroudchi M, Yeganeh F, Samsami Dehaghini A, Ghaderi A. CTLA-4 gene polymorphism in southern Iranian patients with Graves' disease. *French Society of Immunology 2002 Annual Meeting, November 27-29, 2002; Strasbourg, France.*